Leptomeningeal disease (LMD) in melanoma patients is associated with significant neurological sequela and has a dismal outcome, with survival measured typically in weeks. Despite the therapeutic benefit of targeted therapies and immunotherapies for Stage IV melanoma, patients with LMD do not typically benefit. A deeper understanding of the tumor microenvironment (TME) of LMD may provide more appropriate therapeutic selection. A retrospective analysis of subjects who underwent surgical resection with LMD (n=8) were profiled with seven color multiplex staining to evaluate the expression of the global immune suppressive hub - the signal transducer and activator of transcription 3 (STAT3) and for the presence of CD3+ T cells, CD68+ monocyte-derived cells, CD163+ immune suppressive macrophages, and CD11c+ cells [potential dendritic cells (DCs)] in association with the melanoma tumor marker S100B and DAPI for cellular nuclear identification. High-resolution cellular imaging and quantification was conducted using the Akoya Vectra Polaris. CD11c+ cells predominate in the TME (10% of total cells), along with immunosuppressive macrophages (2%). Another potential subset of DCs co-expressing CD11c+ and the CD163+ immunosuppressive marker is frequently present (8/8 of specimens, 8%). Occasional CD3+ T cells are identified, especially in the stroma of the tumor (p=0.039). pSTAT3 nuclear expression is heterogeneous in the various immune cell populations. Occasional immune cluster interactions can be seen in the stroma and on the edge. In conclusion, the TME of LMD is largely devoid of CD3+ T cells but is enriched in immune suppression and innate immunity.

Keywords: melanoma, LMD, tumor microenvironment, T cells, dendritic cells, macrophages, STAT3
INTRODUCTION

Metastasis to the central nervous system (CNS) remains one of the most common and devastating complications of advanced melanoma. Up to 60% of metastatic melanoma patients are clinically diagnosed with CNS disease (1), which is a frequent site of treatment failure among patients treated with approved targeted and immune therapies. Among melanoma patients with CNS metastases, those with LMD have the worst outcomes, with overall survival from diagnosis of typically weeks to a few months (1, 2). Patients with parenchymal brain metastases have multiple treatment options including surgery, stereotactic radiosurgery, systemic therapies including the BRAF and MEK inhibitors, monotherapy with the immune checkpoint inhibitors ipilimumab or pembrolizumab, and/or the combination ipilimumab and nivolumab, which have demonstrated efficacy in clinical trials for metastatic melanoma patients with parenchymal brain metastases (3–8). In contrast, there are very few treatment options for LMD patients (9, 10), especially once patients develop LMD while on these agents. Notably, LMD often causes severe neurological deficits that can critically impact quality of life. Currently, the National Comprehensive Cancer Network guidelines recommend palliative radiotherapy and best supportive care for metastatic melanoma patients with LMD. As the incidence of LMD is rising, the focus on developing more effective treatments for LMD addresses an unmet clinical need of high clinical significance.

A major limitation for the use of immune checkpoint inhibitors or other types of modulators of tumor-mediated immune suppression for CNS malignancies is the low pre-existing immune T cell infiltration (11). Monotherapies directed at inhibition of operational immune suppressive mechanisms (i.e., maintenance of an effector response) would not be expected to exert significant therapeutic effects in the setting of CNS malignancies that have a paucity of T cells. Combinations of immunomodulatory agents targeting several modalities of the immune systems in vivo have the potential to tip the balance of immunosuppressive and immune-stimulatory signals within the tumor microenvironment to favor immune activation and targeted clearance of tumor. In melanoma, abundant innate immune infiltration of the TME (12) and the activation of STAT3 (13) has been shown to play a role in both tumorigenesis and the generation of immune suppression. Specifically, STAT3 expression in macrophages limits their activation (14) and inflammatory responses (15). When STAT3 is expressed within DCs, there is decreased maturation and decreased expression of MHC II, CD80, CD86, and IL-12, rendering them unable to stimulate T cells and to generate antitumor immunity (16). Expression of STAT3 in T cells abrogates their effector functions and induces Tregs (17). The immune composition of melanoma LMD throughout the tumor microenvironment has not been evaluated before, and current single cell techniques such as flow cytometry, single cell sequencing and CyTOF disrupt the tumor architecture and are deconstructive strategies that fail to provide tissue integration and spatial analysis. Therefore, to understand the immune modulation and composition of melanoma LMD more deeply, we conducted a retrospective study of human tissues that focus on observing the immune composition and profile created in the leptomeningeal space in melanoma LMD through seven color multiplex staining technique and high-resolution imaging.

MATERIALS AND METHODS

Study Approval

Under an IRB-approved protocol, we identified patients that underwent surgical resection of melanoma metastasis to the leptomeningeal space from 1994 till 2019. All patients were screened based on a radiographic diagnosis of CNS leptomeningeal disease. Patient demographics and clinicopathological findings were collected from the electronic medical record (Table 1).

Tissue Selection

Melanoma resections from the CNS that could have included the adjacent leptomeningeal space in subjects who had radiographic evidence of LMD were obtained from subjects ≥ 18 years old. Surgery indications in these patients is rare and is based on either establishing the diagnosis or for the alleviation of neurological symptoms thereby limiting the number of specimens available.

Tissue Processing and Orientation

The tissue extracted by the surgeon was immediately fixed in 10% formalin and embedded in paraffin. Slides are created at 4 micrometers of thickness.

Conventional Immunohistochemistry (IHC)

Each antibody was validated with conventional IHC before being incorporated into the multiplex panel. This technique consists of applying the primary antibody with its correspondent polymer in

| Table 1 | Demographics of melanoma patients with LMD. |
|----------|---------------------------------------------|
| Age | Sex | Diagnosis | Location in the CNS | Pre-Op treatment |
| 57 | F | Melanoma/LMD | Cerebellum | Dabrafenib, Trametinib |
| 29 | M | Melanoma/LMD | Cerebellum | Chemotherapy |
| 38 | F | Melanoma/LMD | Occipital lobe | None |
| 74 | F | Melanoma/LMD | Temporal lobe | None |
| 63 | F | Melanoma/LMD | Cerebellum | Chemotherapy, IL-2, Ipilimumab |
| 62 | M | Melanoma/LMD | Occipital Lobe | Radiosurgery, Ipilimumab, Nivolumab |
| 45 | M | Melanoma/LMD | Temporal lobe | Allogeneic vaccine, whole brain radiation, chemotherapy |
| 57 | M | Melanoma/LMD | Frontal Lobe | Radiosurgery, Pembrolizumab, Dabrafenib |
conjunction with DAB color development and hematoxylin stain. Preparation and rehydration of formalin-fixed paraffin-embedded tissue slides are done by incubation in a series of xylene (3x), 100% (2x), 95% (2x) and 75% ethanol (2x) solutions for 5 min each. Antigen retrieval is then performed by heating the slides at 120°C for 12 min while incubated in a specific antigen retrieval buffer (pH6 or pH 9, depending on the antibody used). Afterwards, the slides are washed and incubated in hydrogen peroxide quenching solution (10% methanol, 3% H2O2, and 87% pure water) for 15 min at room temperature (RT). A protein blocker is applied to the slides for 15 min at RT before applying the corresponding primary antibody. Final processing consists of applying the primary antibody specific polymer, coloring, and scanning.

**Multiplex Immunohistochemistry Staining**

Each antibody was validated using conventional immunohistochemistry and monoplex immunofluorescence staining in conjunction with the corresponding opal fluorophore and the spectral DAPI counterstain. The antibodies were tested at three different dilutions, starting with manufacturer recommended dilution (MRD), MRD/2, and MRD/4 with 1/100 tyramide to select the optimal concentration of antibody capable of generating the best signal. The signal was then optimized through different tyramide titrations until generation of the best exposure time ranging from 5 to 25ms. Reproducibility was evaluated using: a positive control of each antibody with DAPI and a DAPI-alone slide. The negative controls included one unstained slide for auto-fluorescence compensation, a tyramide-alone slide treated with hydrogen peroxide for endogenous peroxidase masking, and finally a secondary antibody with tyramide slide. The following antibodies were used in the multiplex panel analysis: S100B Leica NCL-L-S100167 1/100 pH6 with Tyr480 1/200; pSTAT3 Cell Signaling Tyr705 D3A7 XP 1/200 pH 6 with Tyr520 1:150; CD68 Agilent PG-M1 1:50 pH 9 with Tyr570 1:150; CD3 Agilent clone F7.2.38 1:50 with pH 6 buffer for antigen retrieval with Tyr620 1:300; CD163 Abcam EPR19518 1:500 pH 9 with Tyr690 1:100; and CD11c Abcam EP1347Y 1:300 pH 9 with Tyr780 1:100.

**Image Processing**

Slides were scanned with the Vectra Polaris Imaging System (Akoya) following the manual’s instructions using the Fluorescent Mode with high power field scan (40x). The microscope captures the multispectral fluorescent spectra, separately, at the corresponding tyramide Opal fluorophore wavelength with empirically determined exposure times. These captures are then stacked in one image without disrupting the unique fluorescent spectral signature of the markers. Phenochart software was used to visualize the images and stamp them. Finally, spectrally unmixed component images were reconstructed and exported for further analysis using Visiopharm software.

**Image Analysis and Quantification**

All digitized unmixed images were analyzed using the Visiopharm software platform (Hørsholm, Denmark). Regions of interest (ROI) (e.g., tumor, stroma/infiltrative edge) were identified by a board-certified pathologist and transferred to the Visiopharm platform. To analyze cells within the different compartments, a series of customized algorithms were applied to all images and ROI. First, in order to exclude sample regions in which there was excessive bleeding, we trained a deep learning classifier (U-Net architecture) to identify these areas and exclude them from further analysis. Next, for the remaining tissue areas, we used a second Deep Learning algorithm (U-Net architecture) to identify DAPI positive nuclei and then expanded that boundary to approximate the true borders of the cell. The cell segmentation was confirmed via visual inspection using the membrane labels in the staining panel. Once cellular boundaries were confirmed, we used a directed approach to generate the targeted list of biomarker combinations in the samples: CD3, CD68, CD11c, and CD163 individual markers, dual CD68 CD11c, CD68 CD163, CD11c CD163, and triple CD68 CD11c CD163 combinations. For a given cell, the classification of each biomarker was gated using two independently controlled parameters: signal intensity and percent coverage. During the development of the classification algorithm, biomarker classification was visually inspected and, if needed, classification parameters were adjusted to maximize accuracy and minimize the number of false positives and false negatives for each biomarker. Once the parameters were optimized, the batch analysis cascade was applied to all images in the dataset. The results obtained were finally received and saved in Excel sheet format document.

**Statistical Analysis**

For each cell marker or combined markers, a paired Wilcoxon test was performed to test whether there is difference in the percentages of cell populations between tumor area and stroma. Furthermore, in each area (tumor and stroma) another comparison using the same test was performed for each cell marker or combined markers depending on the expression of pSTAT3. At the end, p-values were obtained.

**RESULTS**

**Highlighted Immune Findings in Melanoma LMD**

All specimens included a nodular LMD tumor which was the surgical intent of the resection and 3/8 of these specimens also included the distinctive leptomeningeal spread along the meninges (Figure 1A). Associated with the leptomeningeal component were surrounding immunosuppressive CD163+ macrophages (3/3) (Figure 1B). Occasional T cells could be identified (2/3) in proximity to the leptomeningeal spread. In the areas of tumor perivascular cufﬁng, CD163+ single cells were the dominant immune population (Figure 1C). No CD11c+ single cells are noted in these regions.

In the nodular regions of the melanoma, the tumor vasculature demonstrated immune infiltration of both T cells and...
macrophages (Figure 1D). T cells were usually seen in the tumor stroma (Figure 1E). In comparison to the immune populations in the regions of leptomeningeal spread, the immune microenvironment in the melanoma nodule were enriched with CD11c+ single cells seen in the tumor and the stroma. Dual co-expressing CD11c+ and CD163+ cells were also present in the TME. Occasional interactions between CD11c+ single cells and T cells (4/8) could be seen in the tumor stroma (Figure 1F). Interactions of CD163+ macrophages and T cells were identified at the edge of the tumor and the brain (3/8) (Figure 1G). In general, these cluster interactions occurred between cells that lacked expression of pSTAT3, although pSTAT3 expression was a frequent finding in all the specimens (8/8) (Figure 2A).

**T Cells Partition to the Tumor Stroma**
CD3+ T cells typically localize to the stroma within the tumor (p=0.039) (Figure 2B). Despite no significant differences in the frequency of pSTAT3 expressing immune cells in regions of tumor relative to the stroma (Figure 2C), there was a higher frequency of pSTAT3+ T cells in the tumor (Figure 3).

**CD11c+ Cells Are Enriched in LMD Disease**
There was robust infiltration of melanoma with CD11c+ expressing cells (CD11c+ single cells and dual CD11c+CD163+ cells (Figure 2B), representing a mean of 10% and 8% of total cells, respectively, that lack pSTAT3 expression (Figure 3A), indicating antigen presentation capacity. Nonetheless, there was also a substantial population of CD11c+pSTAT3+ and co-expressing CD11c+CD163+pSTAT3+ cells, suggesting the presence of immune suppression/dysfunction.

In 4/8 of the specimens, especially in the stroma, T cells were observed in close proximity to dual CD11c+CD163+ cells that lacked pSTAT3 expression reflective of antigen presentation capacity to T cells (Figure 3B). In contrast, pSTAT3+ expressing immune cells were generally seen isolated within the tumor and stroma (Figure 3C).

**CD163+ Macrophages Are Frequent in LMD**
CD163+ macrophages diffusely infiltrate tumor and stroma with no significant difference between the different areas (mean of 2% between all specimens in the tumor and stroma) (Figure 2B). No difference was detected between the frequency of pSTAT3+ macrophage populations in the tumor and the stroma (Figure 2C) and there was heterogeneity of pSTAT3 expression within macrophages in the different areas of the tumor similar for T cells and CD11c+ cells.

**DISCUSSION**
This study describes the immune composition within melanoma metastasis to the leptomeningeal space using high resolution cell imaging. As mentioned before, this is a rare oncological population for analysis, since most patients rapidly succumb to
their disease, and surgical resection is rarely indicated. Our study subjects had radiographically confirmed LMD and underwent surgical resection for an adjacent mass secondary to neurological symptoms or to determine a diagnosis. In order to evaluate potential immune therapeutic strategies that might be rationally selected, a basic understanding of the immune composition of LMD must be the first step. STAT3 has been shown to play a critical role in melanoma brain metastasis (18). Our study indicates that this is an operational mechanism in the setting of LMD in a wide variety of infiltrating immune cells. As such, blood-brain-barrier penetrant inhibitors that are in clinical trials, such as WP1066 (NCT01904123), may be a viable therapeutic strategy. In contrast, T cell infiltration was an uncommon event in this setting, and these cells were usually confined to areas of bulky tumor stroma. Given this fact, strategies like STING agonists that generate tumor infiltration of T cells into the TME may need to be considered if an immune checkpoint inhibitor therapy approach is being employed. Similar to gliomas, LMD in melanoma patients appears to demonstrate an enrichment of innate immune cells like CD68+ single cells (monocyte-derived cells) and CD163+ single cells or macrophages. The predominant CD163 expression in these innate immune cells suggest polarization towards immune suppression; therapeutic strategies that polarize these cells to a more favorable pro-inflammatory phenotype such as CSF-1R inhibitors (19), STING agonists (20), and/or anti-PD-1 (21), could therefore be considered in this context. CSF1 inhibitors may further enhance the anti-tumor efficacy of BRAF inhibition in preclinical models (22) and could also be considered.

CD11c+ single cells are present in the TME of LMD but many of those CD11c+ cells also demonstrated co-expression of CD163. We postulate that these cells might not be immune suppressive but rather inflammatory DCs, where they have been described in association with CD3+ T cells during lupus nephritis (23). These dual CD11c+CD163+ expressing cells have also been identified in adipose tissues (24). They have been shown to positively correlate with T cell infiltration and prolonged survival in oropharyngeal cancers (25). Recently, Inna Smalley et al. showed that the presence of DC3 in the TME, which is a new subset of DCs expressing the CD163 marker among others (26), was associated with increased overall survival in patients with melanoma CNS metastases regardless of the tumor location and treatment (27). Despite the description of this unique immune cell population by others, the immunological functional consequence of this phenotype is unknown and may be contextual. DCs, especially the cDC1
subset, if present in the TME of brain tumors, may be an important contributor of antigen presentation and T cell activation (28) and can serve as a biomarker for a positive response to immunotherapies. In contrast, their absence is correlated to poor prognosis (29, 30). The functional consequences of these newly identified immune subset will need to be elucidated and indicates the current lineage characterization, especially in the context of cancer, is insufficient. With the burgeoning use of multiplex immunohistochemistry and mass cytometry, the identification of new immune states and phenotypes will likely requiring revision of designations based on immune functional characterization. Thus, subsets of DCs that have been described thus far may go well beyond the classical definitions of plasmacytoid DCs and myeloid cDC1 and cDC2. In several inflammatory diseases and cancers, the involvement of CD11c+DCs has been shown to activate T cells and induce an effective immune response. If the DC-T cell interactions observed in the TME represents an early activation event of T cells that is happening within the TME before irreversible T cell exhaustion, reversing the hypothesis that T cells activation happens in the peripheral cervical lymph nodes, then the presence of this interactions may be a novel biomarker predictive of responses to immune checkpoint inhibitors.

In addition to the descriptive nature of our study, several additional limitations exist mostly involving the small number of subjects that impeded sufficient statistical power to draw meaningful conclusions regarding specific immunological findings relative to patient outcomes. In addition, we acknowledge that using only seven markers is insufficient to completely characterize the different immune cell phenotypes of the TME and thus additional complementary identification analysis are needed. Correlation of the association of various immune cells with a validation dataset from the Cancer Genome Atlas would have been beneficial, but unfortunately, melanoma LMD cases are not available. Tissue segmentation also posed technical challenges since identifying specimens to interrogate the tumor/CNS interface was limited due to tissue banking protocols that tended to enrich for specimens that had larger amounts of relatively pure tumor, and fewer specimens containing adjacent normal tissues. Nonetheless, this characterization provides insights into applicable therapeutic strategies, although it will need additional interrogation of the functional immunological consequences of the newly identified subsets.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
AUTHOR CONTRIBUTIONS

Conception and Design: SDF and ABH. Data analysis and interpretation: HN, AM, CH, JL, JTH, ICGO, PUK, DAW, PC, JKB, and ABH. Manuscript writing: HN and ABH. Accountable for all aspects of the work: All authors. All authors contributed to the article and approved the submitted version.

FUNDING

The funding agencies including the NIH R01 NS120547 and Codiak BioSciences Inc had no role in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

REFERENCES

1. Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, et al. Leptomeningeal Disease in Melanoma Patients: An Update to Treatment, Challenges, and Future Directions. Pigment Cell Melanoma Res (2020) 33(4):527–41. doi: 10.1111/pcmr.12861
2. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, et al. Predictors of Survival in Metastatic Melanoma Patients With Leptomeningeal Disease. J Neurooncology (2019) 142(3):499–509. doi: 10.1007/s11060-019-03121-2
3. Tawbi HA, Forsyth PA, Aligazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med (2018) 379(8):722–30. doi: 10.1056/NEJMoa1805453
4. Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. J Clin Oncol (2019) 37(1):52–60. doi: 10.1200/JCO.18.00204
5. Becco P, Gallo S, Poletto S, Frascione MPM, Crotto L, Zaccagna A, et al. Melanoma Brain Metastases in the Era of Targeted Therapies: An Overview. Cancers (Basel) (2020) 12(6):1640. doi: 10.3390/cancers12061640
6. Long GV, Trefzer U, Davies MA, Keeford RF, Ascierio PA, Chapman PB, et al. Dabrafenib in Patients With Val600Glu or Val600Lys BRAF-Mutant Melanoma Metastatic to the Brain (BREAK-MB): A Multicentre, Open-Label, Phase 2 Trial. Lancet Oncol (2012) 13(11):1087–95. doi: 10.1016/S1470-2045(12)70431-X
7. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in Patients With Melanoma and Brain Metastases: An Open-Label, Phase 2 Trial. Lancet Oncol (2012) 13(5):459–65. doi: 10.1016/S1470-2045(12)70090-6
8. Goldberg SR, Gettigner SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for Patients With Melanoma or Non-Small-Cell Lung Cancer and Untreated Brain Metastases: Early Analysis of a Non-Randomised, Open-Label, Phase 2 Trial. Lancet Oncol (2016) 17(7):976–83. doi: 10.1016/S1470-2045(16)30053-5
9. Tétu P, Sirven-Villaros L, Cuzzubbo S, Ursu R, Baroudjian B, Delyon J, et al. Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients With Leptomeningeal Metastases. Cancers (Basel) (2020) 12(9):2635. doi: 10.3390/cancers12092635
10. Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA. Managing Leptomeningeal Metastases in the Era of Immune and Targeted Therapy. Int J Cancer (2016) 138(9):1195–201. doi: 10.1002/ijc.31047
11. Weiss SA, Zito C, Tran T, Heishima K, Neumeister V, McGuire J, et al. Melanoma Brain Metastases Have Lower T-Cell Content and Microvessel Density Compared to Matched Extracranial Metastases. J Neurooncology (2021) 152(1):15–25. doi: 10.1007/s11060-020-03619-0
12. Klarquist JS, Janssen EM. Melanoma-Infiltrating Dendritic Cells: Limitations and Opportunities of Mouse Models. Oncoimmunology (2012) 1(9):1584–93. doi: 10.4161/onci.22660
13. Fu X-Q, Liu R, Wang Y-P, Li J-K, Zhu P-L, Li T, et al. Activation of STAT3 is a Key Event in TLR4 Signaling-Mediated Melanoma Progression. Cell Death Dis (2020) 11(4):246. doi: 10.1038/s41419-020-2440-1
14. O’Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways. EMBO J (1998) 17(4):1006–18. doi: 10.1093/emboj/17.4.1006
15. Lin T, Bost KL. STAT3 Activation in Macrophages Following Infection With Salmonella. Biochem Biophys Res Commun (2004) 321(4):828–34. doi: 10.1016/j.bbrc.2004.07.039
16. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 Signaling in the Hematopoietic System Elicits Multicomponent Antitumor Immunity. Nat Med (2005) 11(12):1314–21. doi: 10.1038/nm1325
17. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 Regulates FOXP3 Expression in Human CD4+CD25+ Regulatory T Cells Through a STAT-Dependent Mechanism and Induces the Expansion of These Cells In Vivo. Blood (2006) 108(5):1571–9. doi: 10.1182/blood-2006-02-007447
18. Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, et al. Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis. Cancer Res (2008) 68(23):9634–42. doi: 10.1158/0008-5472.CAN-08-1149
19. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Qualil DF, et al. CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression. Nat Med (2013) 19(10):1264–72. doi: 10.1038/nm.3337
20. Martin GR, Blomquist CM, Henare KL, Jirk FR. Stimulator of Interferon Genes (STING) Activation Exacerbates Experimental Colitis in Mice. Sci Rep (2019) 9(1):14281. doi: 10.1038/s41598-019-50656-5
21. Rao G, Katha K, Ott M, Sibbath A, Mariessy A, Ling X, et al. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res (2020) 26(17):4699–712. doi: 10.1158/1078-0432.CCR-19-4110
22. Mok S, Tsoi J, Koya RC, Hu-Lieskovsk S, West BL, Bollag G, et al. Inhibition of Colony Stimulating Factor-1 Receptor Improves Antitumor Efficacy of BRAF Inhibiting Braf Mutation. BMC Cancer (2015) 15(1):356. doi: 10.1186/s12885-015-1377-y
23. Parikh SV, Malvar A, Shapiro J, Turman JM, Song H, Albertson V, et al. A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis. Front Immunol (2021) 12:621039. doi: 10.3389/fimmu.2021.621039
24. Nakajima S, Koh V, Kua LF, So J, Davide L, Lim KS, et al. Accumulation of Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis. Front Immunol (2021) 12:621039. doi: 10.3389/fimmu.2021.6000095
25. Santegoets SJ, Duurland CL, Jordonova EJ, van Ham VJ, Ehsan I, Loof NM, et al. CD163+ Cytokine-Producing cDC2 Stimulate Intratumoral Type 1 T Cell Responses in HPV16-Induced Oropharyngeal Cancer. J Immunother Cancer (2020) 8(6):e001053. doi: 10.3389/jimmunol.2020.001053
26. Amon L, Lehmann CHK, Heger L, Heidkamp GF, Dudiak D. The Ontogenetic Path of Human Dendritic Cells. Mol Immunol (2020) 120:122–9. doi: 10.1016/j.molimm.2020.02.010
27. Smalley I. Single Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases, in: Abstract Presentation at...
Srivastava S, Jackson C, Kim T, Choi J, Lim M. A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. Cancers (Basel) (2019) 11(4):537. doi: 10.3390/cancers11040537

Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A Natural Killer-Dendritic Cell Axis Defines Checkpoint Therapy-Responsive Tumor Microenvironments. Nat Med (2018) 24(8):1178–91. doi: 10.1038/s41591-018-0085-8

Tucci M, Passarelli A, Mannavola F, Felici C, Stucci LS, Cives M, et al. Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Front Oncol (2019) 9(1148). doi: 10.3389/fonc.2019.01148

Conflict of Interest: AH serves on the advisory boards of Caris Life Sciences and WCG Oncology, receives royalties on licensed intellectual property from Celldex Therapeutics and DNAtrix, and received research support from Codiak BioSciences Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Najem, Marisetty, Horbinski, Long, Huse, Glitza Oliva, Ferguson, Kumthekar, Wainwright, Chen, Lesniak, Burks and Heimberger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.